Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes

References

• Anderton MJ, Manson MM, Verschoyle R, et al. (2004). Mager DE. Physiological modelling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 32:632–8
   PubMed Web of Science ®Google Scholar
• Baker SD, Sparreboom A, Verweij J. (2006). Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45:235–52
   PubMed Web of Science ®Google Scholar
• Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B. (2012). Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 92:40–9
   PubMed Web of Science ®Google Scholar
• Belani CP. (2005). Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer 50:S3–8
   PubMed Web of Science ®Google Scholar
• Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. (2007). A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 13:2768–76
   PubMed Web of Science ®Google Scholar
• Brown RP, Delp MD, Lindstedt SL, et al. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–84
   PubMed Web of Science ®Google Scholar
• Chen L, Sha X, Jiang X, et al. (2013). Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. Int J Nanomedicine 8:73–84
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, et al. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–16
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Edginton AN, Theil FP, Schmitt W, Willmann S. (2008). Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143–52
   PubMed Web of Science ®Google Scholar
• Engels FK, Sparreboom A, Mathot RA, Verweij J. (2005). Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 93:173–7
   PubMed Web of Science ®Google Scholar
• Engels FK, Verweij J. (2005). Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 41:1117–26
   PubMed Web of Science ®Google Scholar
• Eskens FA, Tresca P, Tosi D, et al. (2014). A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. Br J Cancer 110:2170–7
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Valero V, Ahmadi MA, Booser D. (2001). Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 108:994–5
   PubMed Web of Science ®Google Scholar
• Fabbri F, Carloni S, Brigliadori G, et al. (2006). Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biol 7:6
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. (2009). Impact of nanotechnology on drug delivery. ACS Nano 3:16–20
   PubMed Web of Science ®Google Scholar
• Ferraresi V, Milella M, Vaccaro A, et al. (2000). Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol 23:132–9
   PubMed Web of Science ®Google Scholar
• Figg WD, Woo S, Zhu W, et al. (2010). A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol 183:2219–26
   PubMed Web of Science ®Google Scholar
• Gligorov J, Lotz JP. (2004). Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9:3–8
   PubMed Web of Science ®Google Scholar
• Hu TM, Hayton WL. (2001). Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3:E29
   PubMedGoogle Scholar
• Hu ZY, Lu J, Zhao Y. (2014). A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br J Pharmacol 171:2778–89
   PubMed Web of Science ®Google Scholar
• Kagan L, Gershkovich P, Wasan KM, Mager DE. (2011). Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. AAPS J 13:255–64
   PubMed Web of Science ®Google Scholar
• Khalil F, Läer S. (2011). Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011:137–43
   Google Scholar
• Leamon CP, Low PS. (1991). Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 88:5572–6
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. (1995). Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134–44
   PubMed Web of Science ®Google Scholar
• Li C, Ren S, Dai Y, et al. (2014). Efficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxel. AAPS PharmSciTech 15:417–24
   PubMed Web of Science ®Google Scholar
• Li X, Tian X, Zhang J, et al. (2011). In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. Int J Nanomedicine 6:1167–84
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Fenton C. (2005). Docetaxel: a review of its use in metastatic breast cancer. Drugs 65:2513–31
   PubMed Web of Science ®Google Scholar
• Marre F, Sanderink GJ, de Sousa G, et al. (1996). Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296–302
   PubMed Web of Science ®Google Scholar
• Meno-Tetang GM, Li H, Mis S, et al. (2006). Physiologically based pharmacokinetic modelling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34:1480–7
   PubMed Web of Science ®Google Scholar
• Mizushima Y, Hamano T, Yokoyama K. (1982). Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann Rheum Dis 41:263–7
   PubMed Web of Science ®Google Scholar
• Nestorov I. (2007). Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235–49
   PubMed Web of Science ®Google Scholar
• Nicolini A, Giardino R, Carpi A, et al. (2006). Metastatic breast cancer: an updating. Biomed Pharmacother 60:548–56
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A. (2012). Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92:50–61
   PubMed Web of Science ®Google Scholar
• Rudek MA, Chang CY, Steadman K, et al. (2014). Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemother Pharmacol 73:729–36
   PubMed Web of Science ®Google Scholar
• Sharma V, McNeill JH. (2009). To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–21
   PubMed Web of Science ®Google Scholar
• Valero V, Holmes FA, Walters RS, et al. (1995). Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886–94
   PubMed Web of Science ®Google Scholar
• Wang H, Xu Y, Zhou X. (2014). Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation. Int J Mol Sci 15:3519–32
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang J, Jiang T, et al. (2011). Protective effect of Coenzyme Q(10) against oxidative damage in human lens epithelial cells by novel ocular drug carriers. Int J Pharm 403:219–29
   PubMed Web of Science ®Google Scholar
• Waxman DJ, Dannan GA, Guengerich FP. (1985). Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 24:4409–17
   PubMed Web of Science ®Google Scholar
• Wonganan P, Zamboni WC, Strychor S, et al. (2009). Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Cancer Gene Ther 16:405–14
   PubMed Web of Science ®Google Scholar
• Woods CM, Zhu J, McQueney PA, et al. (1995). Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506–26
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Watanabe K, Hayashi M, Awazu S. (1984). Effect of egg yolk phospholipids plasma elimination and tissue distribution of coenzyme Q10 administered in an emulsion to rats. J Pharm Pharmacol 36:766–7
   PubMed Web of Science ®Google Scholar
• Yvon AM, Wadsworth P, Jordan MA. (1999). Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10:947–59
   PubMed Web of Science ®Google Scholar
• Zhao L, Wei YM, Zhong XD, et al. (2009). PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 49:989–96
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang L, Grillo JA, et al. (2011). Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259–67
   PubMed Web of Science ®Google Scholar
• Zhao X, Bi K, Wang X, et al. (2013). A UFLC-MS/MS method coupled with one-step protein precipitation for determination of docetaxel in rat plasma: comparative pharmacokinetic study of modified nanostructured lipid carrier. J Pharm Biomed Anal 83:202–8
   PubMed Web of Science ®Google Scholar